Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation

Method development for the separation of monoclonal antibody charge variants in cation exchange chromatography, Part I: Salt gradient approach

(2015) Szabolcs Fekete et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality

(2014) Kurt Brorson et al.   CURRENT OPINION IN BIOTECHNOLOGY

In vitro and in vivo modifications of recombinant and human IgG antibodies

(2014) Hongcheng Liu et al.   mAbs

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography–mass spectrometry

(2013) Jia-Ming Yang et al.   ANALYTICAL BIOCHEMISTRY

Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques

(2013) Daniel Ayoub et al.   mAbs

Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry

(2013) Liangjie Tang et al.   mAbs

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Characterization of Therapeutic Antibodies and Related Products

(2012) Alain Beck et al.   ANALYTICAL CHEMISTRY

Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media

(2012) Jun Luo et al.   BIOTECHNOLOGY AND BIOENGINEERING

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

(2012) F. J. Beurskens et al.   JOURNAL OF IMMUNOLOGY

Worldwide experience with biosimilar development

(2011) Mark McCamish et al.   mAbs

C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo

(2010) Bing Cai et al.   BIOTECHNOLOGY AND BIOENGINEERING

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Development trends for human monoclonal antibody therapeutics

(2010) Aaron L. Nelson et al.   NATURE REVIEWS DRUG DISCOVERY

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Glycosylation as a strategy to improve antibody-based therapeutics

(2009) Roy Jefferis   NATURE REVIEWS DRUG DISCOVERY

C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes

(2008) Lawrence W. Dick et al.   BIOTECHNOLOGY AND BIOENGINEERING